Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 price target on shares of Trevena in a research note on Thursday, November 14th.

Trevena Trading Up 16.8 %

NASDAQ:TRVN opened at $1.74 on Monday. The company has a 50-day moving average price of $1.71 and a 200-day moving average price of $2.44. Trevena has a 12 month low of $1.13 and a 12 month high of $14.75. The stock has a market cap of $1.50 million, a price-to-earnings ratio of -0.04 and a beta of 1.08.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.